Allotment of acquisition cost decided by the Swedish Tax Agency

2012-12-20 - 15:00

In connection with Vitrolife’s distribution of the shares in Xvivo Perfusion AB, the Swedish Tax Agency has decided that 77% of the acquisition cost should be allotted to Vitrolife AB and 23% to Xvivo Perfusion AB.

Further information can be found on the Swedish Tax Agency’s website and at

Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on December 20, at 3:00 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.